Analysis of Therapeutic Effects of Huanglian Polysaccharide Adjuvant Therapy on T2DM patients with insulin resistance

Abstract

Background The study explored the therapeutic effect of Huanglian polysaccharide adjuvant therapy on type 2 diabetes mellitus (T2DM) patients complicated with insulin resistance. Methods: A total of 100 T2DM patients with insulin resistance in our hospital were selected from April 2019 to September 2020 and randomly divided into control group (n=50) and observation group (n=50). The control group was given metformin combined with insulin glargine while the observation group was given Huanglian polysaccharide combined with insulin glargine. The clinical efficacy, and insulin-related and blood rheological indexes of the two groups before and after treatment were compared. Results: After treatment, the total effective rate of observation group was significantly higher than that of control group (P<0.05). After treatment, the insulin sensitivity index (IAI) of the two groups was significantly higher than that before treatment (P<0.05), the insulin resistance index (IRI) and fasting insulin (FINS) of the two groups were significantly lower than those before treatment (P<0.05), but the IAI level of observation group was significantly higher than that of control group (P<0.05), while the IRI and FINS levels of observation group were significantly lower than those of control group (P<0.05). After treatment, the levels of whole blood high-cut reduction viscosity, whole blood low-cut reduction viscosity, plasma viscosity and fiber protein (FIB) in the two groups were significantly lower than those before treatment (P<0.05), and the levels in observation group were significantly lower than those of control group (P<0.05). Conclusion: The adjuvant therapy of Huanglian polysaccharide has obvious therapeutic effects on T2DM patients with insulin resistance and can significantly improve the insulin-related and blood rheological indexes of patients.